News Guardant Health, Inc.

Equities

GH

US40131M1099

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-10 pm EDT			5-day change	1st Jan Change
22.37 ^USD	+15.07%		+18.49%	-17.30%

May. 10	Guardant Health Shares Rise After Q1 Adjusted Loss Shrinks, Revenue Rises; 2024 Revenue Guidance Raised	MT
May. 09	Earnings Flash (GH) GUARDANT HEALTH Reports Q1 Revenue $168.5M, vs. Street Est of $150.1M	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Guardant Health Shares Rise After Q1 Adjusted Loss Shrinks, Revenue Rises; 2024 Revenue Guidance Raised	May. 10	MT
Guardant Health : Q1 2024 Earnings Call - Presentation	May. 09	PU
Guardant Health: Q1 Earnings Snapshot	May. 09	AQ
Earnings Flash (GH) GUARDANT HEALTH Reports Q1 Revenue $168.5M, vs. Street Est of $150.1M	May. 09	MT
Transcript : Guardant Health, Inc., Q1 2024 Earnings Call, May 09, 2024	May. 09
Guardant Health Reports First Quarter 2024 Financial Results and Increases 2024 Revenue Guidance	May. 09	BU
Guardant Health, Inc. Raises Financial Guidance for the Full Year of 2024	May. 09	CI
Guardant Health to Participate in Upcoming Investor Conferences	May. 07	BU
Guardant Health Surpasses 500 Peer-Reviewed Publications Milestone	May. 07	BU
Canaccord Genuity Adjusts Price Target on Guardant Health to $30 From $45, Maintains Buy Rating	Apr. 29	MT
FDA Advisory Panel Review of Guardant Health's Shield Blood Test to Screen for Colorectal Cancer to Be Held on May 23	Apr. 23	AQ
Sector Update: Health Care Stocks Increase Late Afternoon	Apr. 22	MT
Sector Update: Health Care Stocks Rise in Monday Afternoon Trading	Apr. 22	MT
Guardant Health Says FDA Advisory Panel Will Review Shield Blood Test for Colorectal Cancer Screening; Shares Rise	Apr. 22	MT
FDA Advisory Panel Review of Guardant Health’s Shield™ Blood Test to Screen for Colorectal Cancer to Be Held on May 23	Apr. 22	BU
Guardant Health to Report First Quarter 2024 Financial Results on May 9, 2024	Apr. 18	BU
Goldman Sachs Adjusts Guardant Health Price Target to $28 From $32, Maintains Buy Rating	Apr. 15	MT
Guardant Health to Present Data Highlighting Application of Epigenomics to Advance Precision Oncology at 2024 AACR Annual Meeting	Apr. 03	BU
Guardant Health to Present Data Highlighting Application of Epigenomics to Advance Precision Oncology at 2024 AACR Annual Meeting	Apr. 03	CI
Guardant Health - Royal Marsden And Guardant Health Partnership Provides State-of-the-art Blood Test To Benefit Lung Cancer Patients In Expanded NHS Study	Mar. 25	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Guardant Health, Inc.

Equities

GH

US40131M1099

Summary

Filters